IP Library Granted Patent US 11,691,982
Granted Patent B2
US 11,691,982 · App. 17/019,063 · Granted Jul 4, 2023

Thailanstatin analogs

Inventors: Vasu Jammalamadaka (Dublin, CA); Sanjeev Satyal (San Carlos, CA); Hoyoung Huh (Portola Valley, CA)
Assignee: pH Pharma Co., Ltd.
C07D493/10A61K45/06A61K47/6803A61K47/6841A61K47/6855A61K47/6867A61P35/00C07D493/04
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,691,982
App. No.
17/019,063
Granted
Jul 4, 2023
Kind
B2
Abstract

The invention provides novel cytotoxic compounds and cytotoxic conjugates comprising these cytotoxic compounds and cell-binding agents. More specifically, this invention relates to novel thailanstatin A analogs, useful as cytotoxic small molecule toxins in antibody-drug conjugates (ADCs). The present invention further relates to compositions including these cytotoxic compounds and ADCs, and methods for using these toxins and ADCs to treat pathological conditions including cancer.

Claims (28)

1. A compound of Formula (II):

or a pharmaceutically acceptable salt thereof, wherein:

L is a linker;

R is selected from the group consisting of: —(CH 2 ) n —R 1 ; -5 to 6 membered heteroaryl, where heteroaryl is optionally substituted with one or more of halogen, —CF 3 , —C 1-6 alkyl, and —O—C 1-6 alkyl;

—C(R 2 )═N—R 3 ; —CH(CF 3 )NH(CH 2 ) m CH 3 ; —C(R a R b )NH(CH 2 ) m CH 3 ;

—C(halogen)=CH(CH 2 ) m CH 3 ; —SO 2 —NH(CH 2 ) m CH 3 ; —O(CO)-aryl; —O(CO)-heteroaryl;

—NR a R b ; and —NH-heteroaryl;

wherein R 1 is —O—CR a R b (CH 2 ) m CH 3 or —N—CR a R b (CH 2 ) m CH 3 ;

wherein R a and R b , together with the atoms to which they are joined, form a C 3-10 heterocyclyl ring;

R 2 is —CN or —NH(CH 2 ) m CH 3 ;

R 3 is —(CH 2 ) m CH 3 or —O—(CH 2 ) m CH 3 ;

each n is independently 1, 2, or 3; and

each m is independently 0, 1, 2, or 3.

2. The compound according to claim 1 , wherein L is selected from the group consisting of Formula (A 1 ), Formula (A 2 ), Formula (A 3 ), Formula (A 4 ), and Formula (A 5 ):

wherein q is 3, 4, 5, 6, 7, 8, 9, or 10; and

Y is Br, I, or

3. The compound according to claim 1 , wherein R is selected from the group consisting of:

4. The compound according to claim 1 , having structure 10:

5. A compound of Formula (II):

or a pharmaceutically acceptable salt thereof, wherein:

L is a linker; and

R is selected from the group consisting of

6. The compound according to claim 5 , wherein L is selected from the group consisting of Formula (A 1 ), Formula (A 2 ), Formula (A 3 ), Formula (A 4 ), and Formula (A 5 ):

wherein q is 3, 4, 5, 6, 7, 8, 9, or 10; and

Y is Br, I, or

7. The compound according to claim 1 , wherein R is:

8. The compound according to claim 1 , wherein R is:

9. The compound according to claim 1 , wherein R is:

Assignments (3)
RELEASE OF SECURITY INTEREST Recorded Nov 14, 2024
From: THE THEO GROUP
To: PEAK BIO, INC.
Reel/Frame 069263/0109 →
SECURITY INTEREST Recorded Jul 23, 2024
From: PEAK BIO, INC.
To: THE THEO GROUP
Reel/Frame 068057/0851 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 17, 2023
From: JAMMALAMADAKA, VASU; SATYAL, SANJEEV; HUH, HOYOUNG
To: PH PHARMA CO., LTD.
Reel/Frame 063673/0391 →
Continuity (5)
Division 16376540 · Apr 5, 2019
Division 16135287 · Sep 19, 2018
Provisional Application 62686781 · Jun 19, 2018
Provisional Application 62561060 · Sep 20, 2017
Related Publication 20200407369A1 · Dec 31, 2020